Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of beclometasone dipropionate and chlorhexidine dihydrochloride is not a standard pharmaceutical product for the treatment of asthma. Beclometasone dipropionate is a synthetic glucocorticoid corticosteroid used as an anti-inflammatory agent in respiratory and dermatological conditions. Chlorhexidine dihydrochloride is a biguanide antiseptic used for its broad-spectrum antimicrobial properties, typically in topical or oral hygiene products. Based on the provided trial context involving Chiesi and the comparison of HFA and CFC pMDIs (Clenil Compositum 250), the name provided appears to be an error for the fixed-dose combination of **beclometasone dipropionate and salbutamol**. In that intended combination, beclometasone serves as an inhaled corticosteroid (ICS) to manage airway inflammation, while salbutamol acts as a short-acting beta-2 adrenergic receptor agonist (SABA) to provide bronchodilation. Chiesi developed an HFA-propelled version of this combination to replace the older CFC-propelled Clenil Compositum formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclometasone dipropionate + chlorhexidine dihydrochloride.